MK-7684A

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-7684A, covering 2025-08-14 to 2025-08-14. Get the full timeline:

Most recent: Clinical Trial Update: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) [Phase 2]

See pricing